Skip to content

Wave Life Sciences WVE Contract Liabilities, Non-Current

Contract Liabilities, Non-Current at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS

Other financials

Income statement

See full
Revenue$38.2M+317%
Operating income-$31.3M+37.2%
Net income-$26.1M+44.4%
EPS (diluted)-$0.13+55.2%

Balance sheet

See full
Cash & equivalents$544.6M+124%
Total debt$15.7M-33.4%
Total equity$511.7M+198%
Total assets$583.5M+102%

Cash flow

See full
Operating cash flow-$59.6M+5.5%
CapEx$438.0K+165%
Free cash flow-$60.0M+5.1%

Valuation

See full
Market cap$1.14B+13.0%
Enterprise value$615.92M-22.3%
P/S15.1×-12.2×

Profitability

See full
Operating margin-75.7%-33.6pp
Net margin-66.5%-29.9pp
FCF margin-27.2%-12.6pp

Returns & leverage

See full
Return on equity-53.7%
Debt / equity-0.1×
Current ratio11.3×+8.3×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's contract liabilities, non-current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Wave Life Sciences's contract liabilities, non-current?
Wave Life Sciences (WVE) reported contract liabilities, non-current of $14.6M in Q1 2026.
How has Wave Life Sciences's contract liabilities, non-current changed year-over-year?
Wave Life Sciences's contract liabilities, non-current increased by 161.4% year-over-year, from $5.58M to $14.6M.
What is the long-term trend for Wave Life Sciences's contract liabilities, non-current?
Over 5 years (2020 to 2025), Wave Life Sciences's contract liabilities, non-current has grown at a -28.4% compound annual growth rate (CAGR), from $41.48M to $7.8M.